Literature DB >> 1536947

Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats.

W Witt1, B Baldus, P Bringmann, L Cashion, P Donner, W D Schleuning.   

Abstract

rDSPA alpha 1 (recombinant Desmodus salivary plasminogen activator alpha 1) is a recombinant protein corresponding to a natural plasminogen activator from the vampire bat Desmodus rotundus. The thrombolytic properties of rDSPA alpha 1 and tissue-type plasminogen activator (t-PA) were compared in a rat model of pulmonary embolism. Whole blood clots, produced in vitro and labeled with 125I-fibrinogen, were embolized into the lungs of anesthetized rats. Thrombolysis was calculated from the difference between initial clot radioactivity and that remaining in the lungs at 60 minutes. Blood was sampled for gamma counting, measurement of hemostatic factors, and plasminogen activator antigen levels. Thrombolysis at 3, 10, 30, and 100 nmol/kg intravenously (10% bolus, 90% over 60 minutes) amounted to 30% +/- 2%, 51% +/- 4%, 85% +/- 4%, 98% +/- 0% for rDSPA alpha 1 and 30% +/- 3%, 41% +/- 3%, 57% +/- 6%, 93% +/- 2% for t-PA (controls: 29% +/- 2%; mean +/- SEM, n greater than or equal to 6). t-PA at 100 nmol/kg significantly decreased fibrinogen, plasminogen, and alpha 2-antiplasmin levels by 33% +/- 7%, 38% +/- 8%, and 61% +/- 9%, whereas rDSPA alpha 1 at 100 nmol/kg only lowered alpha 2-antiplasmin significantly (by 29% +/- 6%). Compared with t-PA, rDSPA alpha 1 is the more potent and more clot selective (fibrin specific) thrombolytic agent. These results suggest that rDSPA alpha 1 may be safer and more efficacious than currently used thrombolytics.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1536947

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Inhibition of desmoteplase-induced fibrinolytic activity in vitro.

Authors:  Johannes J M L Hoffmann; Oliver Kops
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

Review 2.  Trends and future developments in the pharmacological treatment of acute ischaemic stroke.

Authors:  G J del Zoppo; S Wagner; M Tagaya
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

3.  Ventilation/perfusion imaging in a rat model of airway obstruction.

Authors:  Nilesh N Mistry; Yi Qi; Laurence W Hedlund; G Allan Johnson
Journal:  Magn Reson Med       Date:  2010-03       Impact factor: 4.668

Review 4.  Desmoteplase: discovery, insights and opportunities for ischaemic stroke.

Authors:  Robert L Medcalf
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  Potential for a New Coronary Thrombolytic Plateau.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 6.  Novel thrombolytic drugs: will they make a difference in the treatment of ischaemic stroke?

Authors:  Atte Meretoja; Turgut Tatlisumak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 7.  Relationship of neurovascular elements to neuron injury during ischemia.

Authors:  Gregory J del Zoppo
Journal:  Cerebrovasc Dis       Date:  2009-04-03       Impact factor: 2.762

Review 8.  Thrombolytic agents in development.

Authors:  M Verstraete; H R Lijnen; D Collen
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

Review 9.  Novel thrombolytic agents.

Authors:  M Verstraete; H R Lijnen
Journal:  Cardiovasc Drugs Ther       Date:  1994-12       Impact factor: 3.727

Review 10.  Rodent models of pulmonary embolism and chronic thromboembolic pulmonary hypertension.

Authors:  Andrei A Karpov; Dariya D Vaulina; Sergey S Smirnov; Olga M Moiseeva; Michael M Galagudza
Journal:  Heliyon       Date:  2022-02-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.